Natural endo/exogenous or synthetic PRRs agonists, such as Toll-like receptor (TLR) ligands, retinoic acid-inducible gene-I (RIG-I)-like receptors (RLRs) ligands, and stimulator of interferon genes (STING) agonists, have been applied in several preclinical and clinical studies for cancer treatment [131,132]. Here, STING1 is linked to cancer.